Similar articles

• Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.

  Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Chit A, et al. Lancet Infect Dis. 2015 Dec;15(12):1459-66. doi: 10.1016/S1473-3099(15)00249-2. Epub 2015 Sep 8. Lancet Infect Dis. 2015. PMID: 26362172 Clinical Trial.
• Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

  Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V. Tsang P, et al. Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11. Vaccine. 2014. PMID: 24120672 Clinical Trial.
• Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

  DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. DiazGranados CA, et al. N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727. N Engl J Med. 2014. PMID: 25119609 Clinical Trial.
• Reduced-dose influenza vaccine.

  Wyatt KN, Ryan GJ, Sheerin KA. Wyatt KN, et al. Ann Pharmacother. 2006 Sep;40(9):1635-9. doi: 10.1345/aph.1G645. Epub 2006 Jul 11. Ann Pharmacother. 2006. PMID: 16835314 Review.
• Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis.

  Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, Mahmud SM. Wilkinson K, et al. Vaccine. 2017 May 15;35(21):2775-2780. doi: 10.1016/j.vaccine.2017.03.092. Epub 2017 Apr 18. Vaccine. 2017. PMID: 28431815 Review.